Semaglutide Dosage Chart: 250mcg/Week Protocol

Semaglutide is a GLP-1 receptor agonist that suppresses appetite, delays gastric emptying, and improves glucose-dependent insulin secretion. It has extensive clinical trial data — FDA-approved for both weight loss and type 2 diabetes.

Research-context information only. Semaglutide is the active ingredient in FDA-approved products for type 2 diabetes and chronic weight management; research-peptide and compounded forms are not FDA-approved and are sold for research purposes only. Protocols, doses, and reactions reported below come from clinical trials and community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Research peptide protocols use much lower doses than pharmaceutical formulations due to variable potency and purity. This is not medical advice.

Quick Reference: Standard Protocol

Community-reported protocol parameters (self-reported; compiled from community dosing logs and reconstitution guides — documentation of what sources describe, not a recommendation):

Self-reported starting doses begin around 125 mcg weekly for 2-4 weeks to assess tolerance, before increasing to 250 mcg.

Cycling Details

Standard cycle: 250 mcg weekly for 8 weeks on, 8 weeks off. The slow titration (125 mcg weeks 1-4, then 250 mcg weeks 5-8) mimics FDA-approved protocols that emphasize gradual increases for tolerability.

Community protocols describe extensions to 12-16 weeks for weight-loss-focused cycles; a smaller subset self-report doses up to 500 mcg weekly. Community sources most commonly describe 250 mcg as sufficient for appetite suppression at the research-peptide level.

Routes of Administration

Subcutaneous injection is the only route for injectable semaglutide.

• Sites: Rotate between abdomen, thigh, and upper arm. Community sources describe the abdomen as offering the most consistent absorption.
• Volume: ~0.17 mL with an insulin syringe (29-31 gauge)
• Timing: Once weekly, same day each week in most reported protocols
• IM injection — community sources do not describe IM protocols, citing concern over faster absorption

Reconstitution Quick Reference

The following reflects dilution ratios documented in community reconstitution sources:

Math: 3 mg / 2 mL = 1.5 mg/mL = 1,500 mcg/mL. For 250 mcg: 250 / 1,500 = 0.167 mL = ~17 units.

Protocols describe swirling gently rather than shaking. Storage protocols describe refrigeration at 2-8°C; community sources describe 28-day use windows. For step-by-step instructions, see the full Semaglutide Reconstitution Guide.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

Community research peptide doses are dramatically lower than FDA-approved pharmaceutical doses.

FDA-approved weight loss dose: 2.4 mg/week after titration (0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg). The STEP 1 trial showed 14.9% weight loss at 2.4 mg/week over 68 weeks (Wilding et al., 2021).

FDA-approved diabetes dose: 0.25-1 mg/week maintenance. Cardiovascular benefit demonstrated in SUSTAIN-6 (Marso et al., 2016).

Why community doses are ~10x lower: Research peptides have variable potency and purity compared to pharmaceutical-grade semaglutide (Novo Nordisk). The community starts at doses equivalent to the lowest FDA titration step (0.25 mg) and increases cautiously. Some people are highly sensitive to GLP-1 agonists — starting low allows assessment of individual tolerance.

Stacking Protocols

Stacking with other GLP-1 agonists (tirzepatide, liraglutide) is described as redundant — overlapping mechanisms increase side effects without proportional benefits. Published data also flags hypoglycemia risk when combined with insulin or diabetes medications.

Side Effects & Safety

• Nausea — 44% in STEP trials, most common side effect, dose-dependent
• Diarrhea — 30% in trials
• Vomiting — 24% in trials
• Constipation — 24% in trials
• Stomach pain — 20% in trials
• Pancreatitis — rare but documented; trials flagged severe abdominal pain for discontinuation and evaluation
• Gallbladder problems — rapid weight loss increases gallstone risk
• Thyroid C-cell tumors — the FDA black box warning for the approved semaglutide products cites contraindication in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2)
• Most GI side effects improve within 4-8 weeks and are reduced by slower titration

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). For research-grade compounded semaglutide vials, the conversion from a target mg dose to syringe units depends entirely on the dilution chosen at reconstitution. Semaglutide is the active ingredient in FDA-approved injectable products that ship pre-filled and require no syringe math; the conversions below apply to research-grade compounded forms only.

Reconstitution A: 5 mg vial + 2 mL BAC water (2.5 mg/mL) — practical mid-range dilution where 1 mg = 40 units.

Reconstitution B: 5 mg vial + 1 mL BAC water (5 mg/mL) — half the volume per dose, useful when a 2.4 mg target would otherwise approach the syringe limit.

These conversions reflect the dilutions documented in published reconstitution protocols and community sources. They report how reconstitution math is described, not a recommended dosing schedule.